Nabgen, Inc.
Publicly observedDurham, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Durham | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Nabgen, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | JHTFFFJPHKL7 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Aug 2026Publicly observed
NIH SBIR/STTR award: Development of a universal approach to block inhibitors for protein replacement therapy
USD 312,461.00 · National Center for Advancing Translational Sciences · Source: NIH RePORTER (opens in a new tab)
- Grant1 Apr 2023Publicly observed
NIH SBIR/STTR award: Novel strategy to block AAV neutralizing antibody activity
USD 1,014,676.00 · National Center for Advancing Translational Sciences · Source: NIH RePORTER (opens in a new tab)
- Grant1 Apr 2023Publicly observed
NIH SBIR/STTR award: Novel strategy to block AAV neutralizing antibody activity
USD 993,865.00 · National Center for Advancing Translational Sciences · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.